SUSTAIN trial programme (revision 3)
Old revision·21:36, 2 Aug 2024·ForestPlotFinn
This is an old revision of this page, as it stood at 21:36, 2 Aug 2024, saved by ForestPlotFinn with the summary add the run-in period, which changes how the baseline reads. It may differ substantially from the current revision, and any error it contains may since have been corrected.
| SUSTAIN trial programme | |
|---|---|
| Drug | Semaglutide 0.5 and 1.0 mg weekly |
| Indication | Type 2 diabetes |
| Notable member | SUSTAIN 6, cardiovascular outcomes |
| Topic infobox · conventions | |
The SUSTAIN trial programme is the phase 3 series that established weekly semaglutide for type 2 diabetes. Its trials compared semaglutide against placebo and against active comparators including sitagliptin, exenatide extended-release, insulin glargine and dulaglutide.[1]
Across the programme, semaglutide 1.0 mg reduced glycated haemoglobin by roughly 1.5–1.8 percentage points from baseline, with weight reduction of about 4–6 kg — substantially less than the 2.4 mg obesity dose studied in STEP.[1]
Structure of the programme
[edit]| Trial | Comparator | Principal finding |
|---|---|---|
| SUSTAIN 1 | Placebo | HbA1c −1.5% at 1.0 mg |
| SUSTAIN 2 | Sitagliptin | Greater HbA1c and weight reduction |
| SUSTAIN 3 | Exenatide extended-release | Greater HbA1c and weight reduction |
| SUSTAIN 4 | Insulin glargine | Greater HbA1c reduction, weight loss vs gain |
| SUSTAIN 6 | Placebo, CV outcomes | MACE HR 0.74 (0.58–0.95) |
| SUSTAIN 7 | Dulaglutide | Greater HbA1c and weight reduction |
Active-comparator trials are more informative than placebo trials for a class with several members, and SUSTAIN 7 is one of relatively few head-to-head comparisons within the GLP-1 class.[1]